During the last session, Relay Therapeutics Inc (NASDAQ:RLAY)’s traded shares were 2.11 million, with the beta value of the company hitting 1.64. At the end of the trading day, the stock’s price was $2.61, reflecting an intraday loss of -5.43% or -$0.15. The 52-week high for the RLAY share is $10.72, that puts it down -310.73 from that peak though still a striking 32.18% gain since the share price plummeted to a 52-week low of $1.77. The company’s market capitalization is $442.45M, and the average intraday trading volume over the past 10 days was 3.46 million shares, and the average trade volume was 2.40 million shares over the past three months.
Relay Therapeutics Inc (RLAY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.27. RLAY has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 5 recommend a Buy rating for it.
Relay Therapeutics Inc (NASDAQ:RLAY) trade information
Relay Therapeutics Inc (RLAY) registered a -5.43% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.43% in intraday trading to $2.61, hitting a weekly high. The stock’s 5-day price performance is 13.48%, and it has moved by -20.67% in 30 days. Based on these gigs, the overall price performance for the year is -61.79%. The short interest in Relay Therapeutics Inc (NASDAQ:RLAY) is 18.06 million shares and it means that shorts have 6.63 day(s) to cover.
The consensus price target of analysts on Wall Street is $19, which implies an increase of 86.26% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16 and $25 respectively. As a result, RLAY is trading at a discount of -857.85% off the target high and -513.03% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.05%. While earnings are projected to return 11.33% in 2025, the next five years will return 1.33% per annum.
RLAY Dividends
Relay Therapeutics Inc is due to release its next quarterly earnings on 2025-Feb-25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders
Relay Therapeutics Inc insiders own 1.80% of total outstanding shares while institutional holders control 104.10%, with the float percentage being 106.01%. SB INVESTMENT ADVISERS (UK) LTD is the largest shareholder of the company, while 280.0 institutions own stock in it. As of 2024-06-30, the company held over 27.9 million shares (or 21.0093% of all shares), a total value of $181.94 million in shares.
The next largest institutional holding, with 11.7 million shares, is of VANGUARD GROUP INC’s that is approximately 8.8125% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $76.32 million.
Also, the Mutual Funds coming in first place with the largest holdings of Relay Therapeutics Inc (RLAY) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 4.86 shares. This amounts to just over 2.87 percent of the company’s overall shares, with a $12.68 million market value. The same data shows that the other fund manager holds slightly less at 4.05, or about 2.39% of the stock, which is worth about $10.57 million.
